Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

Share Price is delayed by 15 minutes
Get Live Data
3179.00    95.00 (3.08%)
Bid:
3186.00
Ask:
3188.00
Spread: 2.00 (0.063%)
Market Cap: £4.43b
CRDA Live PriceLast checked at - London Stock Exchange

Intraday Croda International Share Chart

Interim Management Statement

31 Oct 2013 07:00

RNS Number : 8098R
Croda International PLC
31 October 2013
 



 

31 October 2013

 

 

Croda International Plc

 

 

Interim Management Statement

 

 

Croda International Plc ("Croda") today announces its interim management statement for the period since 1 July 2013.

 

Trading

 

Sales trends improved again during the third quarter with growth across all regions despite subdued underlying market conditions, similar to those experienced during the first half of the year. Turnover was up 4.4% to £267.9m (2012: £256.5m) with underlying sales* up 0.8%. The significant devaluation of the Japanese Yen and Indian Rupee reduced the benefit of currency translation compared to the first half.

 

Innovation led sales were very strong in all segments with double digit growth seen in new and patented products. However, we saw near double digit declines in relatively low margin but high volume commodity and toll manufacturing sales.

 

Operating margins remained solid at 23.1% (2012: 23.2%) despite slight dilution due to the acquisition of Sichuan Sipo Chemical Co ("Sipo"), with continuing operating profit up 4.0% to £62.0m (2012: £59.6m). Group pre-tax profit increased 5.4% to £58.6m (2012: £55.6m) in the quarter.

 

In Consumer Care, sales were up 3.2% to £145.4m (2012: £140.9m) supported by both volume growth and a better quality product mix. Overall trends were mixed. Personal Care sales continued to improve with strong sales in Western Europe and North America, although we saw sales decline again in Eastern Europe, Middle East and Africa. Crop Care made further progress following its return to growth in June, although whilst we saw strong double digit turnover increases in Europe, growth was more modest elsewhere. Health Care sales were also up in the quarter compared to the same period in 2012. Operating profit increased 3.2% to £45.6m (2012: £44.2m). Return on sales in the quarter was 31.4% (2012: 31.4%).

 

In Performance Technologies sales were up 0.4% to £95.0m (2012: £94.7m) with growth in Geotech and Polymer Additives. Home Care and Coatings & Polymers were both down with particularly weak sales in North America. Lubricants saw sales decline in Europe. The Group currency benefit is skewed towards Performance Technologies due to its relatively high exposure to European markets. Operating profit increased 4.5% to £13.9m (2012: £13.3m). Return on sales was 14.6% (2012: 14.0%).

 

Industrial Chemicals continued to see good underlying sales growth which was boosted by the acquisition of Sipo in July 2013. Turnover increased 31.6% to £27.5m (2012: £20.9m). Sipo broke even at the operating profit level which diluted the return on sales in the sector. Operating profit increased 19.0% to £2.5m (2012: £2.1m). Return on sales was 9.1% (2012: 10.0%).

 

* Excluding acquisitions, disposals and currency

 

 

Financial Position

 

Cash generation was very strong in the quarter with net debt falling £8.6m to £213.7m.This was despite a £45.6m increase in borrowings due to the acquisition of 65% of the equity of Sipo in the quarter.

 

 

Commenting on the outlook, Martin Flower, Chairman of Croda said:

 

"Croda has continued to generate a steadily improving underlying sales performance through every quarter of this year despite challenging market conditions. We continue to benefit from the strong demand for innovation and remain particularly encouraged by the progress that Croda is making in Asia and South America. However, with currencies continuing to weaken and market conditions expected to remain subdued, fourth quarter profits are likely to be similar to quarter three. Looking ahead, the Board remains confident that Croda's strategy will continue to deliver progress into 2014 and beyond."

 

For further information please contact:

 

Steve Foots

Group Chief Executive

01405 860 551

Sean Christie

Group Finance Director

01405 860 551

Charlie Armitstead

Pendomer Communications

020 3603 5224

 

 

The company will host a conference call at 8.00am today.

 

Please dial +44 (0) 203 426 2845 and quote "Croda International" to gain access to the call.

 

 

 

 

 

 

Additional Information

 

£m

Q3

9 months

2013

2012

2013

2012

Consumer Care

145.4

140.9

+3.2%

458.2

450.1

+1.8%

Performance Technologies

95.0

94.7

+0.3%

298.2

298.9

-0.2%

Industrial Chemicals

27.5

20.9

+31.6%

74.2

62.8

+18.2%

Continuing turnover

267.9

256.5

+4.4%

830.6

811.8

+2.3%

Consumer Care

45.6

44.2

+3.2%

144.6

140.7

+2.8%

Performance Technologies

13.9

13.3

+4.5%

48.4

46.1

+5.0%

Industrial Chemicals

2.5

2.1

+19.0%

8.1

6.3

+28.6%

Continuing operating profit

62.0

59.6

+4.0%

201.1

193.1

+4.1%

Operating margin

 

23.1%

 

23.2%

24.2%

23.8%

Interest

(3.4)

(4.0)

(9.4)

(12.3)

Continuing pre tax profit

58.6

55.6

+5.4%

191.7

180.8

+6.0%

 

 

 

Analysis of Q3 turnover uplift

Volume

-0.8%

-0.8%

Price/mix

+1.6%

+0.8%

Underlying

+0.8%

+0.0%

Acquisitions

+2.0%

+0.2%

Currency

+1.6%

+2.1%

Increase in continuing turnover

+4.4%

+2.3%

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSDMMFGNGFGFZM
Date   Source Headline
13th Feb 20232:14 pmRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSAcquisition of Solus Biotech
11th Jan 20233:45 pmRNSDirector/PDMR Shareholding
13th Dec 20223:04 pmRNSDirector/PDMR Shareholding
6th Dec 202212:36 pmRNSDirector/PDMR Shareholding
14th Nov 20223:33 pmRNSHolding(s) in Company
11th Nov 20222:04 pmRNSDirector/PDMR Shareholding
11th Nov 202210:37 amRNSDirector/PDMR Shareholding
11th Nov 202210:33 amRNSDirector/PDMR Shareholding
8th Nov 202211:23 amRNSDirector/PDMR Shareholding
7th Nov 20226:11 pmRNSDirector/PDMR Shareholding
7th Nov 20227:00 amRNSJez Maiden to retire as Group Finance Director
3rd Nov 20225:53 pmRNSDirector/PDMR Shareholding
3rd Nov 20225:51 pmRNSDirector/PDMR Shareholding
3rd Nov 20225:51 pmRNSDirector/PDMR Shareholding
3rd Nov 20225:50 pmRNSDirector/PDMR Shareholding
3rd Nov 20225:49 pmRNSDirector/PDMR Shareholding
11th Oct 20221:37 pmRNSDirector/PDMR Shareholding
7th Oct 20228:37 amRNSDirector/PDMR Shareholding
7th Oct 20227:59 amRNSDirector/PDMR Shareholding
7th Oct 20227:00 amRNSInvestor seminar
5th Oct 20224:42 pmRNSDirector/PDMR Shareholding
20th Sep 20229:01 amRNSDirector/PDMR Shareholding
13th Sep 20221:47 pmRNSDirector/PDMR Shareholding
11th Aug 20222:39 pmRNSDirector/PDMR Shareholding
29th Jul 20227:00 amRNSResults for the six months ended 30 June 2022
22nd Jul 20224:50 pmRNSDirectorate Change
12th Jul 20223:08 pmRNSDirector/PDMR Shareholding
1st Jul 20227:00 amRNSCompleted divestment
30th Jun 202212:15 pmRNSTotal Voting Rights
28th Jun 20227:00 amRNSUS Government to support lipid systems expansion
22nd Jun 20229:07 amRNSHolding(s) in Company
17th Jun 20229:46 amRNSHolding(s) in Company
13th Jun 20222:52 pmRNSDirector/PDMR Shareholding
8th Jun 202211:53 amRNSDirector/PDMR Shareholding
7th Jun 20225:23 pmRNSTransaction in Own Shares
7th Jun 20224:08 pmRNSDirector/PDMR Shareholding
7th Jun 20223:27 pmRNSHolding(s) in Company
27th May 202210:48 amRNSHolding(s) in Company
26th May 20227:02 amRNSDirector Declaration
23rd May 20222:34 pmRNSResult of AGM
20th May 20227:21 amRNSAGM trading update
19th May 20223:09 pmRNSDirector/PDMR Shareholding
19th May 20222:17 pmRNSHolding(s) in Company
11th May 20222:15 pmRNSDirector/PDMR Shareholding
11th May 20227:00 amRNSSite visit and investor presentation
3rd May 202210:21 amRNSDirector/PDMR Shareholding
13th Apr 20229:48 amRNSDirector/PDMR Shareholding
7th Apr 20226:15 pmRNSDirector/PDMR Shareholding
31st Mar 20223:12 pmRNSUK Government to support lipid systems expansion

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.